Evotec AG today announced a collaboration with Censo Biotechnologies Ltd. („Censo“) to source and provide patient-derived induced pluripotent stem cells („iPSC“) to support Evotec’s broad iPSC platform. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-ipsc-drug-discovery-leadership-through-strategic-collaboration-with-censo-biotechnologies-5474